XML 48 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Income tax
12 Months Ended
Dec. 31, 2020
Income tax [Abstract]  
Income tax
8.
Income tax

The major components of the income tax expenses for the years ended December 31, 2020, 2019 and 2018 are:

  
2020
£’000
  
2019
£’000
  
2018
£’000
 
Profit or loss
         
Current tax:
         
R&D tax credit for the year
  
(12,432
)
  
(21,767
)
  
(18,486
)
Tax related to share-based compensation plans
  
-
   
-
   
125
 
Foreign corporation tax on profits for the year
  
84
   
152
   
139
 
Adjustments in respect of prior years
  
(100
)
  
43
   
-
 
Total current tax
  
(12,448
)
  
(21,572
)
  
(18,222
)
Deferred tax:
            
Current year
  
(790
)
  
-
   
-
 
Effect of changes in tax rates
  
(1
)
  
-
   
-
 
Movement in unrecognized deferred tax asset
  
351
   
-
   
-
 
Originating and reversal of timing differences, including adjustments in respect of prior years
  
(379
)
  
(686
)
  
1,674
 
Total deferred tax
  
(819
)
  
(686
)
  
1,674
 
Total income tax credit
  
(13,267
)
  
(22,258
)
  
(16,548
)
Tax related to items recognized in other comprehensive income during the year:
            
Current tax related to share-based compensation plans
  
-
   
-
   
(125
)
Deferred tax on fair value movements of available-for-sale financial assets
  
-
   
-
   
(3,509
)
Tax charged to other comprehensive income
  
-
   
-
   
(3,634
)

Reconciliation of tax expense and accounting profit for 2020, 2019 and 2018:


 
2020
  
2019
  
2018
 
  
£
’000
  
£
’000
  
£
’000
 
Loss before tax
  
(87,360
)
  
(126,189
)
  
(88,178
)
Tax credit using the UK Corporation tax rate of 19% (2019: 19% and 2018: 19%)
  
(16,598
)
  
(23,976
)
  
(16,754
)
Effect of:
            
Non-deductible expenses
  
9,120
   
13,148
   
629
 
Income not taxable for tax purposes
  
-
   
-
   
(954
)
Chargeable gain on sale of assets held for sale
  
-
   
-
   
4,359
 
Other permanent differences
  
-
   
(1
)
  
(38
)
Additional deduction for R&D expenditure
  
(16,286
)
  
(29,365
)
  
(13,691
)
Surrender of tax losses for R&D tax credit refund
  
16,286
   
28,523
   
24,223
 
R&D expenditure credits
  
(13,424
)
  
(22,602
)
  
(19,215
)
Credit to other comprehensive income for share-based compensation plans
  
-
   
-
   
125
 
Movement in deferred tax not recognized
  
8,084
   
12,413
   
4,746
 
Adjustments to tax charge in respect of previous periods - deferred tax
  
(379
)
  
(500
)
  
-
 
Adjustments to tax charge in respect of previous periods
  
(100
)
  
43
   
-
 
State taxes
  
7
   
-
   
-
 
Effects of overseas tax rates
  
24
   
-
   
-
 
Effects of tax rates in foreign jurisdictions
  
(1
)
  
59
   
22
 
Total tax credit included in loss for the year
  
(13,267
)
  
(22,258
)
  
(16,548
)

The components of income tax are as follows:

  
2020
£’000
  
2019
£’000
  
2018
£’000
 
Current tax:
         
United States:
         
Federal
  
(16
)
  
100
   
137
 
State
  
(-
)
  
15
   
2
 
United Kingdom
  
(12,432
)
  
(21,687
)
  
(18,361
)
Total current tax
  
(12,448
)
  
(21,572
)
  
(18,222
)
Deferred tax:
            
United States:
            
Federal
  
(819
)
  
(644
)
  
(516
)
State
  
-
   
(42
)
  
(1
)
United Kingdom
  
-
   
-
   
2,191
 
Total deferred tax
  
(819
)
  
(686
)
  
1,674
 
Total income tax credit
  
(13,267
))
  
(22,258
)
  
(16,548
)

Tax related to items recognized in other comprehensive income during the year:

  
2020
£’000
  
2019
£’000
  
2018
£’000
 
United States
  
   
   
 
United Kingdom – current tax
  
   
   
(125
)
United Kingdom – deferred tax
  
   
   
(3,509
)
Tax charged to other comprehensive income
  
   
   
(3,634
)

In September 2016, the U.K. substantively enacted legislation to reduce the main rate of corporation tax from 20% to 19% effective April 1, 2017 and then a further reduction to 17% effective April 1, 2020. On March 11, 2020, the Chancellor of the Exchequer announced that the rate would not reduce on April 1, 2020 and would remain at 19%.

A deferred tax asset of £2,230,000 has been recognized in 2020 (2019: £1,507,000) representing unused tax credits carried forward for Immunocore LLC following an assessment of all available and applicable information, including its forecasts of costs and future profitability and the resulting ability to reverse the recognized deferred tax assets over a short period of time.

In addition to the deferred tax asset above, the Group has unrecognized deferred tax assets on tax losses of £30,827,000 (2019: 20,820,000) which do not expire. Deferred tax assets have not been recognized in respect of these losses as they may not be used to offset taxable profits elsewhere in the Group and there are no other tax planning opportunities or other evidence of recoverability in the near future. If the Group were able to recognize all unrecognized deferred tax assets, the income tax credit would increase by £33,852,000 (2019: £23,007,000).